Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes

Biochemical Pharmacology

Volumn 66, Issue 11, 2003, Pages 2133-2139

  Nishimoto, Tomoyuki ^a   Tozawa, Ryuichi ^a   Amano, Yuichiro ^a   Wada, Takeo ^a   Imura, Yoshimi ^a   Sugiyama, Yasuo ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Geranylgeranyl PP; HMG CoA reductase inhibitor; Rhabdomyosarcoma cell line RD; Skeletal muscle cell; Squalene synthase inhibitor; TAK 475

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTILIPEMIC AGENT; ATORVASTATIN; CELL ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; SIMVASTATIN; SQUALENE; SQUALENE SYNTHASE INHIBITOR; T 91485; TAK 475;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CELL DIFFERENTIATION; CELL LINE; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; INHIBITION KINETICS; LIVER TOXICITY; MUSCLE CELL; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA CELL; SKELETAL MUSCLE;

EID: 0242408817     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.011     Document Type: Article

References (35)

1. Olsson A.G. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am. J. Cardiol. 87:2001;33B-36B.
2. Hsu I., Sprinler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann. Pharmacother. 29:1995;743-759.
3. Brown A.S., Bakker-Arkema R.G., Yellen L., Henley R.W. Jr., Guthrie R., Campbell C.F., Koren M., Woo W., Mclain R., Black D.M. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol. 32:1998;665-672.
4. Ucar M., Mjörndal T., Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 22:2000;441-457.
5. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., Trepel J., Liang B., Patronas N., Venzon D.J., Reed E., Myers C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2:1996;483-491.
6. Flint O.P., Masters B.A., Gregg R.E., Durham S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol. 145:1997;91-98.
7. Flint O.P., Masters B.A., Gregg R.E., Durham S.K. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight protein in neonatal rat muscle cell culture. Toxicol. Appl. Pharmacol. 145:1997;99-110.
8. Omar M.A., Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36:2002;288-295.
9. Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am. J. Cardiol. 73(Suppl.):1994;3D-11D.
10. Knopp R.H. Drug treatment of lipid disorders. N. Eng. J. Med. 341:1999;498-511.
11. Pasternak R.C., Smith S.C. Jr., Bairey N., Grundy S.M., Cleeman J.I., Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 106:2002;1024-1028.
12. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346:2002;539-540.
13. Miki T., Kori M., Mabuchi H., Tozawa R., Nishimoto T., Sugiyama Y., Teshima K., Yukimasa H. Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J. Med. Chem. 45:2002;4571-4580.
14. Nishimoto T., Amano Y., Tozawa R., Ishikawa E., Imura Y., Yukimasa H., Sugiyama Y. Lipid-lowering property of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br. J. Pharmacol. 139:2003;911-918.
15. Amano Y., Nishimoto T., Tozawa R., Ishikawa E., Imura Y., Sugiyama Y. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur. J. Pharmacol. 466:2003;155-161.
16. Sadeghi M.M., Collinge M., Pardi R., Bender J.R. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165:2000;2712-2718.
17. Munro E., Patel M., Chan P., Betterridge L., Clunn G., Gallagher K., Hufhes A., Schachter M., Wolfe J., Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur. J. Clin. Invest. 24:1994;766-772.
18. Vachon P.H., Loechel F., Xu H., Wewer U.M., Engvall E. Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival. J. Cell Biol. 134:1996;1483-1497.
19. Kroll T.G., Peters B.P., Hustad C.M., Jones P.A., Killen P.D., Ruddon R.W. Expression of laminin chains during myogenic differentiation. J. Biol. Chem. 269:1994;9270-9277.
20. Kuroda M., Endo A. Inhibition of in vitro cholesterol synthesis by fatty acids. Biochim. Biophys. Acta. 486:1977;70-81.
21. Ishiyama M., Shiga M., Sasamoto K., Mizoguchi M., He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem. Pharm. Bull. 41:1993;1118-1122.
22. Perez-Sala D., Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199:1993;175-192.
23. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 83:1998;490-500.
24. Matzno S., Tazuya-Murayama K., Tanaka H., Yasuda S., Mishima M., Uchida T., Nakabayashi T., Matsuyama K. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J. Pharm. Pharmacol. 55:2003;795-802.
25. Nakahara K., Kuriyama M., Sonoda Y., Yoshidome H., Nakagawa H., Fujiyama J., Higuchi I., Osame M. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 152:1998;99-106.
26. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., imberg J.J. Decrease in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in human. Clin. Pharmacol. Ther. 57:1995;62-66.
27. Laaksonen R., Jokelainen K., Sahi T., Hörkönen M., Tikkanen M.J., Himberg J.J. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. 77:1995;851-854.
28. Thompson P.D., Nugent A.M., Herbert P.N. Increases in creatinine kinase after exercise in patients treated with HMG-CoA reductase inhibitors. JAMA. 264:1990;2992.
29. Thompson P.D., Zmuda J.M., Domalik L.J., Staggers J., Guyton J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 46:1997;1206-1210.
30. Ogata Y., Takahashi M., Takeuchi K., Ueno S., Mano H., Ookawara S., Kobayashi E., Ikeda U., Shimada K. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J. Cardiovasc. Pharmacol. 40:2002;907-915.
31. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.-C., Najib-Fruchart J., Glineur C., Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 107:2001;1423-1432.
32. Poels P.J., Gabreels F.J. Rhabdomyolysis: a review of the literature. Clin. Neurol. Neurosurg. 95:1993;175-192.
33. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128:2002;159-168.
34. Maiguma T., Fujisaki K., Itoh Y., Makino K., Teshima D., Takahashi-Yanaga F., Sasaguri T., Oishi R. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 367:2003;289-296.
35. Keller R.K. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim. Biophys. Acta. 1303:1996;169-179.